S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

实时更新: Luye Pharma Group Ltd [2186.HK]

交易所: HKSE 工业: Pharmaceuticals, Biotechnology & Life Sciences
最后更新时间26 Apr 2024 @ 16:08

0.74% HKD 2.72

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:08):

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia...

Stats
今日成交量 25.13M
平均成交量 9.60M
市值 10.23B
EPS HKD0 ( 2024-03-28 )
Last Dividend HKD0.0600 ( 2020-06-29 )
Next Dividend HKD0 ( N/A )
P/E 18.13
ATR14 HKD0.00900 (0.33%)

音量 相关性

長: 0.11 (neutral)
短: 0.28 (neutral)
Signal:(47.09) Neutral

Luye Pharma Group Ltd 相关性

10 最正相关
10 最负相关

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Luye Pharma Group Ltd 相关性 - 货币/商品

The country flag 0.00
( neutral )
The country flag 0.31
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.18
( neutral )

Luye Pharma Group Ltd 财务报表

Annual 2023
营收: HKD6.14B
毛利润: HKD4.20B (68.44 %)
EPS: HKD0.140
FY 2023
营收: HKD6.14B
毛利润: HKD4.20B (68.44 %)
EPS: HKD0.140
FY 2022
营收: HKD5.98B
毛利润: HKD4.14B (69.22 %)
EPS: HKD0.170
FY 2021
营收: HKD5.20B
毛利润: HKD3.40B (65.32 %)
EPS: HKD-0.0422

Financial Reports:

No articles found.

Luye Pharma Group Ltd Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)
HKD0
(N/A)

Luye Pharma Group Ltd Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.62 - good (86.18%) | Divividend Growth Potential Score: 4.10 - Potential for dividend initiation, but uncertain (18.00%)
Information
First Dividend HKD0.0370 2016-10-04
Last Dividend HKD0.0600 2020-06-29
Next Dividend HKD0 N/A
Payout Date 2020-07-24
Next Payout Date N/A
# dividends 8 --
Total Paid Out HKD0.406 --
Avg. Dividend % Per Year 0.00% --
Score 2.99 --
Div. Sustainability Score 8.62
Div.Growth Potential Score 4.10
Div. Directional Score 6.36 --
Next Divdend (Est)
(2024-08-02)
HKD0 Estimate 0.00 %
Dividend Stability
0.06 Very Bad
Dividend Score
2.99
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
9922.HK Ex Dividend Knight 2023-06-07 Annually 0 0.00%
2180.HK Ex Dividend Knight 2023-07-03 Annually 0 0.00%
1181.HK Ex Dividend Knight 2023-09-13 Annually 0 0.00%
0257.HK Ex Dividend Junior 2023-09-25 Semi-Annually 0 0.00%
3886.HK Ex Dividend Junior 2023-06-27 Sporadic 0 0.00%
1755.HK Ex Dividend Knight 2023-07-03 Annually 0 0.00%
0798.HK Ex Dividend Junior 2023-06-20 Annually 0 0.00%
2338.HK Ex Dividend Knight 2023-09-28 Semi-Annually 0 0.00%
1313.HK Ex Dividend Junior 2023-09-14 Semi-Annually 0 0.00%
0373.HK Ex Dividend Junior 2023-05-04 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.08671.5008.2710.00[0 - 0.5]
returnOnAssetsTTM0.02091.2009.3010.00[0 - 0.3]
returnOnEquityTTM0.04461.500-0.615-0.923[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM1.3150.8008.426.74[1 - 3]
quickRatioTTM0.8440.8009.747.79[0.8 - 2.5]
cashRatioTTM0.3981.5008.9010.00[0.2 - 2]
debtRatioTTM0.330-1.5004.50-6.76[0 - 0.6]
interestCoverageTTM2.561.000-0.164-0.164[3 - 30]
operatingCashFlowPerShareTTM0.1832.009.9410.00[0 - 30]
freeCashFlowPerShareTTM0.03872.009.9810.00[0 - 20]
debtEquityRatioTTM0.671-1.5007.32-10.00[0 - 2.5]
grossProfitMarginTTM0.6841.0001.9271.927[0.2 - 0.8]
operatingProfitMarginTTM0.1441.0009.119.11[0.1 - 0.6]
cashFlowToDebtRatioTTM0.08211.000-0.655-0.655[0.2 - 2]
assetTurnoverTTM0.2410.800-1.727-1.381[0.5 - 2]
Total Score8.62

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM17.771.0008.310[1 - 100]
returnOnEquityTTM0.04462.50-0.395-0.923[0.1 - 1.5]
freeCashFlowPerShareTTM0.03872.009.9910.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM0.1832.009.9410.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM1.6011.5002.660[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1121.0009.690[0.1 - 0.5]
Total Score4.10

Luye Pharma Group Ltd

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。